Physician profile
Hammad A Saudye
NPI 1013186071
$826.75
in general payments reported to CMS, 2019-2025
10 companies · $23.16 in 2025
The $23.16 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $30.75 · 2021: $85.84 · 2022: $26.32 · 2023: $218 · 2024: $92.33 · 2025: $23.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $333.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $179.10 | 2021-2023 | Ensite Precision |
| Edwards Lifesciences Corporation | $148.25 | 2019 | |
| Cardiovascular Systems INC. | $122.29 | 2019 | |
| Medtronic, INC. | $80.55 | 2023-2025 | Micra, Onyx Frontier, Symplicity G3 |
| Astrazeneca Pharmaceuticals LP | $72.84 | 2019-2020 | |
| Siemens Medical Solutions USA, INC. | $67.62 | 2021 | |
| Lantheus Medical Imaging, INC. | $57.04 | 2019-2024 | |
| Boston Scientific Corporation | $51.87 | 2022-2024 | Resonate El Icd Vr |
| Amgen INC. | $25.27 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.92 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hammad Saudye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.